A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.

Trial Profile

A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cladribine (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma; Lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results (n=24) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 13 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2021 as reported by ClinicalTrials.gov record.
    • 04 Dec 2014 Status changed from recruiting to active, no longer recruiting recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top